A5018111458- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Kruppel-like factors research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Acute Lymphoblastic Leukemia research
- Platelet Disorders and Treatments
- Hematopoietic Stem Cell Transplantation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Liver Disease and Transplantation
- Cytokine Signaling Pathways and Interactions
- Renal Diseases and Glomerulopathies
- Blood groups and transfusion
- Hematological disorders and diagnostics
- Complement system in diseases
- Cell Adhesion Molecules Research
- Erythrocyte Function and Pathophysiology
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2024
University of Cincinnati Medical Center
2024
Hospital Clínic de Barcelona
2014-2023
Universitat de Barcelona
2013-2022
Humboldt-Universität zu Berlin
2021
Freie Universität Berlin
2021
Laredo Community College
2019
KU Leuven
2017
Frankston Hospital
2017
Université Paris Cité
2016-2017
Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no to interferon alfa. We compared efficacy imatinib that alfa combined low-dose cytarabine newly diagnosed CML.
The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML the phase. For 5 years, we followed patients with who received imatinib as initial therapy.We randomly assigned 553 receive then evaluated them overall event-free survival; progression accelerated-phase or blast crisis; hematologic, cytogenetic, molecular responses;...
Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent selective Janus kinase (JAK) 1 2 inhibitor, as compared with best available therapy, in patients myelofibrosis.We assigned 219 intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera post-essential thrombocythemia to receive oral ruxolitinib therapy. The end point key secondary study were percentage at least 35% reduction spleen volume week 48 24, respectively,...
Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on basis of more than 10 years follow-up in CML who were treated imatinib as initial therapy.In this open-label, multicenter trial crossover design, we randomly assigned newly diagnosed phase to receive either or interferon alfa plus cytarabine. Long-term included overall survival, response treatment, serious adverse events.The...
Purpose The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower 10 g/dL, leukocytes higher 25 × 9 /L, circulating blasts ≥ 1%, and constitutional symptoms. main objective of this study was refine DIPSS by incorporating prognostic information from karyotype, platelet count, transfusion status. Patients Methods Mayo Clinic databases PMF were used identify patients with...
We present a review of critical concepts and produce recommendations on the management Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- second-line therapy, therapy for special issues. Key questions were selected according criterion clinical relevance. Statements produced using Delphi process, two consensus conferences involving panel 21 experts appointed by European LeukemiaNet (ELN) convened. Patients with polycythemia vera...
Abstract Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies. COMFORT-II was randomized (2:1), open-label phase 3 study patients myelofibrosis; to BAT could crossover ruxolitinib upon protocol-defined disease progression or after primary end point, confounding long-term comparisons. At week 48, 28% (41/146) of achieved...
IMPORTANCE Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival.Fedratinib, JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF early-phase trials.OBJECTIVE To evaluate the efficacy safety of fedratinib therapy primary or secondary (post-polycythemia vera post-essential thrombocythemia) MF.DESIGN, SETTING, AND PARTICIPANTS...
Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development MPN-directed therapies. We aimed assess utility an abbreviated symptom score for most pertinent representative MPN subsequent serial use assessing response therapy.The Neoplasm Symptom Assessment Form total (MPN-SAF TSS) was calculated as mean 10 items from two previously validated scoring systems. Questions focus on fatigue,...